1.Ultrasound-guided percutaneous aspiration and drainage in the diagnosis and treatment of liver abscess in children:Report of 15 cases
Shubing FANG ; Zhengyu MEI ; Kai YAO
Chinese Journal of Minimally Invasive Surgery 2005;0(09):-
Objective To explore the clinical value of u ltrasound-guided percutaneous aspiration and drainage for bacterial liver absces s in children. Methods Under the guidance of ultrasonography, 15 children with bacterial hepatic abscess underwent percutaneous aspiration or drainage. Among them, 9 were given percutaneous aspiration for 1~4 times, and 6 underwent percutaneous drainage. Results Percutaneous aspirati on or drainage was successfully accomplished in all the 15 children, 14 of whom were cured. The hospital stay was 15~42 days (mean, 26.3 days). No bleeding or b ile leakage happened. Follow-up for 4~12 months (mean, 6.8 months) in 11 childre n showed no recurrence. One patient with no improvement left hospital of his own accord. Conclusions Ultrasound-guided percutaneous aspiration and drainage is a feasible option for the treatment of liver abscess in childre n.
2.Research on the mechanism of mechanical ventilation induced endoplasmic reticulum stress promoting mechanical ventilation-induced pulmonary fibrosis.
Ri TANG ; Jinhua FENG ; Shuya MEI ; Qiaoyi XU ; Yang ZHOU ; Shunpeng XING ; Yuan GAO ; Zhengyu HE ; Zhiyun ZHANG
Chinese Critical Care Medicine 2023;35(11):1171-1176
OBJECTIVE:
To demonstrate the mechanism of mechanical ventilation (MV) induced endoplasmic reticulum stress (ERS) promoting mechanical ventilation-induced pulmonary fibrosis (MVPF), and to clarify the role of angiotensin receptor 1 (AT1R) during the process.
METHODS:
The C57BL/6 mice were randomly divided into four groups: Sham group, MV group, AT1R-shRNA group and MV+AT1R-shRNA group, with 6 mice in each group. The MV group and MV+AT1R-shRNA group mechanically ventilated for 2 hours after endotracheal intubation to establish MVPF animal model (parameter settings: respiratory rate 70 times/minutes, tidal volume 20 mL/kg, inhated oxygen concentration 0.21). The Sham group and AT1R-shRNA group only underwent intubation after anesthesia and maintained spontaneous breathing. AT1R-shRNA group and MV+AT1R-shRNA group were airway injected with the adeno-associated virus one month before modeling to inhibit AT1R gene expression in lung tissue. The expressions of AT1R, ERS signature proteins [immunoglobulin heavy chain-binding protein (BIP), protein disulfide isomerase (PDI)], fibrosis signature proteins [collagen I (COL1A1), α-smooth muscle actin (α-SMA)] in lung tissues were detected by immunofluorescence and Western blotting. Hematoxylin-eosin (HE) staining was used to evaluate lung injury and Masson staining was used to evaluate pulmonary fibrosis.
RESULTS:
Compared with the Sham group, the degree of pulmonary fibrosis and lung injury were more significant in the MV group. In the MV group, the protein expressions of AT1R, BIP, PDI, COL1A1 and α-SMA were increased (AT1R/β-actin: 1.40±0.02 vs. 1, BIP/β-actin: 2.79±0.07 vs. 1, PDI/β-actin: 2.07±0.02 vs. 1, COL1A1/α-Tubulin: 2.60±0.15 vs. 1, α-SMA/α-Tubulin: 2.80±0.25 vs. 1, all P < 0.01). The number of E-cad+/AT1R+ and E-cad+/BIP+ cells in lung tissue increased, and the fluorescence intensity of COL1A1 and α-SMA increased. Compared with the MV group, the degree of pulmonary fibrosis and lung injury were significantly relieved in the MV+AT1R-shRNA group. In the MV+AT1R-shRNA group, the protein expressions of AT1R, BIP, PDI, COL1A1 and α-SMA were decreased (AT1R/β-actin: 0.53±0.03 vs. 1.40±0.02, BIP/β-actin: 1.73±0.15 vs. 2.79±0.07, PDI/β-actin: 1.04±0.07 vs. 2.07±0.02, COL1A1/α-Tubulin: 1.29±0.11 vs. 2.60±0.15, α-SMA/α-Tubulin: 1.27±0.10 vs. 2.80±0.25, all P < 0.01). The number of E-cad+/AT1R+ and E-cad+/BIP+ cells in lung tissue decreased, and the fluorescence intensity of COL1A1 and α-SMA decreased. There was no statistically significant difference in the indicators between AT1R-shRNA group and Sham group.
CONCLUSIONS
MV up-regulate the expression of AT1R in alveolar epithelial cells, activate the AT1R pathway, induce ERS and promote the progression of MVPF.
Mice
;
Animals
;
Pulmonary Fibrosis/chemically induced*
;
Lung Injury
;
Respiration, Artificial/adverse effects*
;
Actins/metabolism*
;
Tubulin
;
Mice, Inbred C57BL
;
Endoplasmic Reticulum Stress
;
RNA, Small Interfering
3.Deferasirox for the treatment of iron overload in thalassemia :a rapid health technology assessment
Junping WANG ; Mei ZHANG ; Guoyu WANG ; Zhengyu WU ; Peng ZHOU ; Jiajia ZHANG ; Lijuan NING ; Shan GAO
China Pharmacy 2022;33(1):90-95
OBJECTIVE To eval uate the effectiveness ,safety and economy of deferasir ox for the treatment of iron overload in thalassemia with rapid health technology assessment ,and to provide evidence-based basis for rational clinical use. METHODS Retrieved from Chinese and English database/website as PubMed ,Embase,Cochrane Library ,NHS EED ,CADTH,CNKI and Wanfang database ,health technology assessment (HTA),systematic evaluation/meta-analysis and pharmacological studies about deferasirox versus deferoxamine/deferiprone for the treatment of iron overload in thalassemia were collected from the inception to June 2021. Based on literature screening and data extraction ,the quality of literature about HTA reports ,systematic evaluation/ Meta-analysis and pharmacoeconomic research were evaluated with HTA checklist ,A Measurement Tool to As sess Systematic Reviews,standard scale of economic evaluation report. The effectiveness and safety results were described quantitatively ,and the economic evaluation results were described qualitatively. RESULTS One HTA report ,five systematic evaluation/meta-analysis and five pharmacoeconomic studies were selected from 1 569 literature. Included HTA reports , systematic evaluation/meta-analysis,pharmacoeconomic studies were high in quality. Most studies reported that 30 mg/(kg·d) deferasirox was E-mail:aydgs@126.com better than deferoxamine in reducing the levels of s erum ferritin and liver iron overload ;ADR induced by deferasirox were mainly gastrointestinal irritation symptoms ,skin itching ,joint pain,transaminase elevation ,etc.,which generally did not affect subsequent treatment. There was no statistical significance in severe ADR between deferoxamine group and deferasirox group [RR =0.96,95%CI(0.85,1.08),P=0.52]. Compared with deferoxamine,deferasirox had higher cost-effectiveness ;but deferasirox was less likely to be cost-effective than deferiprone. CONCLUSIONS Deferasirox has good effectiveness and safety for iron overload in thalassemia ,and has good economic advantages in Britain and Iran ,compared with deferoxamine.